Log in

Implementation strategy of ICH guideline Q3D

The purpose of this paper is to address specific considerations to enable the practical implementation of ICH Guideline for Q3D Elemental Impurities in the European Union. It is Intended to Provide Guidance for Applicants / MAHs, drug product, drug substance and vehicle manufacturers, as well as regulators. In addition to new applications, it will aussi apply to changes to Existing authorized medicinal products.


Scientific guidelines with recommendations SmPC

The European Medicines Agency HAS released a detailed list of all relevant guidelines with SmPC (Summary of Product Characteristics) recommendations have an overview and media for marketing permission holders.


Q11 Development and Manufacture of Drug Substances Q & A (Regarding the selection and justification of starting materials)

This draft guidance, When finalized, will Represent the current thinking of the Food and Drug Administration (FDA or Agency) is this topic. It Does not suit les Any rights for Any Person and is not binding on FDA or the public. You can use an alternative approach if it satisfying the requirements of the applicable statutes and règlements.


Concept paper on the need for revision of Note for guidance on quality of water for pharmaceutical use (H + V)

The current guideline needs to be updated to Reflect imminent exchange in European Pharmacopoeia. The text of guideline needs to be updated to take into account manufacturing practices using methods --other than distillation for Producing water of injectable quality and therefore the deletion of the monograph Water, highly purified. A new Ph. Eur. monograph "Water for preparation of extracts" (2249) est aussi disponible.


Final Guidance for Industry and FDA Staff: Current Good Manufacturing Practice Requirements for Combination Products

This guidance Describes and Explains the final rule on current Good Manufacturing Practice (CGMP) requirements for combination products That FDA Issued on January 22, 2013 (final rule).2 (21 Code of Federal Regulations (CFR) from 4). Prior to issuance of the final rule, ALTHOUGH CGMP règlements Were in place to suit les requirements for drugs, devices, biological products, and Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT / Ps), There Were No règlements to Clarify and explain the implementation of These CGMP requirements to combination products. The final rule Did not suit les Any new requirements; It was Intended to Clarify qui CGMP requirements apply When drugs, devices, and biological products are combined to create combination products, and to set forth a transparent and streamlined Regulatory framework for firms to use When Demonstrating compliance with CGMP requirements applicable.


a3p-100pxhaut logo


Commit to share
Transmit and progress together
Promoting innovation

The A3P Association is a major player in the pharmaceutical and biotechnology industry.
Created in 1986, it contributes to the good development of the production of medicines and clean and sterile equipment, it runs a network of professionals 21 000, manufacturers and suppliers, as part of International Congress and technical days.

It now has over 1700 members who share their technical experience, scientific and regulatory.

More info on video (Versiongb - drapeauitalie )

  group    administrators A3P
& Project Managers

letter   newsletter A3P
BROWSER A3P is a tool comprising the majority of links to texts, guides, regulatory documents and websites for the pharmaceutical, biotechnology and biomedical.
  • GMP & Guides

  • Country Sites

  • Regulatory Sites

  • Pharma areas

  • other Sites

   version 1.00                                                                                                               youtube channel   linkedin